Imagine you or a loved one has just had a stroke. In the frantic rush to the hospital, a doctor has to choose which clot-busting drug to give. That single choice could shape your ability to walk, talk, and live independently three months later. A massive review of 21 clinical trials, involving over 16,800 patients, compared all the available drugs given within 4.5 hours of a stroke. The goal was to see which ones help people recover best and which are safest. The findings are striking. Two newer drugs stood out for helping more people achieve an excellent recovery—meaning they could walk and care for themselves with no help. One, called reteplase (given as two 18 mg doses), was better than the standard drug alteplase at helping patients get back to normal. Another, a new version of staphylokinase, showed an even stronger benefit for excellent recovery. On safety, this new staphylokinase also appeared to carry a lower risk of a dangerous brain bleed than one dose of another newer drug, tenecteplase. Importantly, none of the drugs showed a difference in the risk of dying within 90 days. The bottom line is clear: in the race against time after a stroke, the specific medication used is a critical factor for a good outcome.
Reteplase and non-immunogenic staphylokinase show superior functional outcomes vs alteplase in AIS within 4.5hWhich clot-busting drug works best for stroke? Two newer options may help more people walk and talk normally again
AI-generated summary of the cited source, checked by automated accuracy review. How we work
Key Takeaway
Consider reteplase (18+18 mg) and non-immunogenic recombinant staphylokinase (10 mg) for potential functional outcome benefits in AIS patients within 4.5 hours.
This systematic review and network meta-analysis compared the efficacy and safety of intravenous thrombolytic drugs for acute ischemic stroke (AIS) within 4.5 hours of onset. The analysis included 21 randomized controlled trials published up to December 12, 2025, involving a total of 16,837 adult patients. The primary efficacy outcomes were 90-day excellent (modified Rankin Scale [mRS] score 0–1) and good (mRS 0–2) functional outcomes. Safety outcomes were symptomatic intracranial hemorrhage (sICH) and all-cause mortality. A frequentist network meta-analysis using a fixed-effect consistency model was conducted, reporting odds ratios (ORs) with 95% confidence intervals (CIs). For achieving an excellent functional outcome (mRS 0–1), reteplase (18 + 18 mg) showed a statistically significant advantage over alteplase (0.9 mg/kg) (OR 1.60; 95% CI, 1.27–2.02). Non-immunogenic recombinant staphylokinase (10 mg) also demonstrated a statistically significant benefit over the comparator for this outcome (OR 2.23; 95% CI, 1.43–3.48). Reteplase (18 + 18 mg) also improved the likelihood of a good functional outcome (mRS 0–2) compared with alteplase (OR 1.41; 95% CI, 1.08–1.84). Regarding safety, non-immunogenic recombinant staphylokinase significantly reduced the risk of sICH compared with tenecteplase 0.25 mg/kg (OR 0.31; 95% CI, 0.11–0.94). No significant differences in 90-day all-cause mortality were observed among the treatments. The authors concluded that within the 4.5-hour treatment window, reteplase (18 + 18 mg) and non-immunogenic recombinant staphylokinase (10 mg) were associated with the highest probabilities of improved functional outcomes.
What this means for you:
For stroke patients, two newer clot-busting drugs were linked to better recovery odds than the current standard. More on Stroke
Network meta-analysis compares alteplase, tenecteplase, and JX10 for acute ischemic stroke treatment outcomes
New analysis compares three clot-busting drugs for stroke patients treated up to twenty-four hours after symptoms start
This network meta-analysis evaluated intravenous thrombolytic agents for acute ischemic stroke. Alteplase significantly improved functional …
A large review found one standard drug helped more patients walk again than usual care, while a new drug showed promise but needs more testi…
Tenecteplase linked to higher thrombus migration than alteplase in acute ischemic stroke with EVT
Tenecteplase linked to more clot movement than alteplase in stroke patients
This secondary analysis of a randomized controlled trial in 496 patients with intracranial occlusion found that IV tenecteplase was associat…
A study found tenecteplase caused more clot movement than alteplase in stroke patients. This movement was tied to better recovery odds.
Cortical Superficial Siderosis Burden Predicts Hemorrhage and Poor Outcomes After Stroke Thrombolysis
New Brain Scan Marker Predicts Bleeding Risk Before Treatment
A substudy of the AcT trial (alteplase versus tenecteplase) evaluated radiological Boston CAA criteria and constituent markers in 482 thromb…
A specific brain scan pattern predicts dangerous bleeding after clot-busting drugs, helping doctors decide who needs fast treatment to save …
Tirofiban Adjunct Therapy Improves Outcomes in Patients with Inadequate Tenecteplase Response
Trial shows tirofiban improves outcomes for some stroke patients
Intravenous tirofiban significantly improves 90-day functional outcomes for acute ischemic stroke patients failing initial tenecteplase ther…
A new clinical trial suggests that adding tirofiban can improve recovery rates for certain types of stroke patients who do not respond well …
View Original Abstract ↓
BackgroundAlthough several newer thrombolytic agents for acute ischemic stroke (AIS) within 4.5 h of onset have been developed, their relative efficacy, safety, and optimal dosing remain unclear. A comprehensive comparison across all available agents is therefore needed.MethodsWe systematically searched PubMed, Embase, the Cochrane Central Register of Controlled Trials, and Web of Science for English-language reports of randomized controlled trials (RCTs) published up to December 12, 2025. Eligible trials enrolled adult AIS patients treated with intravenous thrombolysis. Primary outcomes were 90-day excellent (modified Rankin Scale [mRS] score 0–1) and good (mRS 0–2) functional outcomes. Safety outcomes were symptomatic intracranial hemorrhage (sICH), and all-cause mortality. A frequentist network meta-analysis using a fixed-effect consistency model was conducted to estimate odds ratios (ORs) with 95% confidence intervals (CIs).ResultsA total of 21 RCTs involving 16,837 patients were included. For achieving mRS 0–1, reteplase (18 + 18 mg) showed a statistically significant advantage over alteplase (0.9 mg/kg) (OR 1.60; 95% CI, 1.27–2.02), and non-immunogenic recombinant staphylokinase (10 mg) demonstrated a statistically significant benefit (OR 2.23; 95% CI, 1.43–3.48). Reteplase (18 + 18 mg) also improved the likelihood of mRS 0–2 compared with alteplase (OR 1.41; 95% CI, 1.08–1.84). For safety, non-immunogenic recombinant staphylokinase significantly reduced sICH risk compared with tenecteplase 0.25 mg/kg (OR 0.31; 95% CI, 0.11–0.94). No significant differences in 90-day mortality were observed among treatments.ConclusionWithin the 4.5-h treatment window, reteplase (18 + 18 mg) and non-immunogenic recombinant staphylokinase (10 mg) were associated with the highest probabilities of improved functional outcomes.Systematic review registrationhttps://www.crd.york.ac.uk/PROSPERO/view/CRD420251152754.
Intravenous tenecteplase improves functional outcomes but increases hemorrhage risk in non-large vessel occlusion acute ischemic stroke
Tenecteplase improves stroke recovery but increases bleeding risk in late treatment window
Related in Neurology
Aging impacts multiple sclerosis pathobiology by shifting inflammation toward chronic, compartmentalized neuroinflammation and neurodegeneration
New research explores how aging changes multiple sclerosis treatment
This narrative review examines the impact of aging on the immunological and neuroinflammatory microenvironment in older patients with multip…
As people age, multiple sclerosis can change from sudden flare-ups to a slow, steady progression of nerve damage.
Tirofiban Adjunct Therapy Improves Outcomes in Patients with Inadequate Tenecteplase Response
Trial shows tirofiban improves outcomes for some stroke patients
Intravenous tirofiban significantly improves 90-day functional outcomes for acute ischemic stroke patients failing initial tenecteplase ther…
A new clinical trial suggests that adding tirofiban can improve recovery rates for certain types of stroke patients who do not respond well …
Immunometabolic dysregulation drives hyperalgesia and hypoesthesia in diabetic peripheral neuropathy
New research explores how inflammation drives nerve damage in diabetes
This narrative review explores the pathophysiology of diabetic peripheral neuropathy, focusing on how hyperglycemia, lipotoxicity, and intes…
Chronic high blood sugar causes more than just high glucose; it triggers a cycle of inflammation and immune stress that damages nerves.
Artificial intelligence shows potential for diagnosis, behavior analysis, and educational support in autism spectrum disorder
Artificial Intelligence Shows Potential to Support Autism Diagnosis and Education
This systematic review of 18 empirical studies evaluates artificial intelligence applications including machine learning, computer vision, a…
New research highlights how artificial intelligence can help identify autism early, analyze social behaviors, and provide personalized educa…
From Other Specialties
Individualized six-phase antithrombotic strategy leads to left ventricular thrombus resolution and neurological recovery
New strategy helps manage heart blood clots after heart attack
This case report describes an individualized six-phase antithrombotic strategy for a 27-year-old male with myocardial infarction, stroke, hy…
A tailored six-phase treatment plan helped a young man recover fully from a stroke and heart attack while successfully clearing dangerous bl…
Heterogeneous definitions and clinical inconsistencies currently hinder the accurate identification of treatment-resistant depression
New ways to define treatment resistant depression are emerging
This narrative review examines the phenotypic definition of treatment-resistant depression (TRD) and its associated biological correlates. T…
Doctors struggle to treat some types of depression because the current definition is inconsistent. New research looks at how biology and beh…
HIFU combined with ethanol ablation or GnRH-a improves intraoperative outcomes for adenomyosis treatment
HIFU Combined With Medication Shows Better Results for Adenomyosis
This network meta-analysis of 1,685 patients evaluated HIFU combined with various medications compared to HIFU alone for adenomyosis. The an…
Combining high-intensity focused ultrasound (HIFU) with specific medications may improve treatment outcomes for people with adenomyosis.
Risk-optimized use of Janus kinase inhibitors in Japanese patients with rheumatoid arthritis depends on comorbidities
New evidence helps doctors choose safer arthritis treatments for seniors
This narrative review examines the safety and risk profile of Janus kinase inhibitors (JAKi) for rheumatoid arthritis specifically within th…
Doctors are moving toward personalized plans for rheumatoid arthritis, focusing on a patient's specific health risks rather than just their …